arginine vasopressin; urine concentration; protein kinase A; cAMP; intracellular calcium THE REGULATED PASSIVE MOVEMENT OF UREA across biological membranes occurs via facilitative urea transporters. In mammals, these proteins are derived from two distinct genes, namely, UT-A (Slc14a2) and UT-B (Slc14a1) (11) . There are six major isoforms derived from the UT-A gene by alternative splicing (UT-A1 to UT-A6) compared with two major UT-B isoforms (UT-B1 and UT-B2) (14, 16, 19) . UT-A1, UT-A2, UT-A3, and UT-B1 are the major renal isoforms, and it has recently been shown that these proteins play a vital role in the urinary concentrating mechanism. Indeed, mouse knockout models have shown that both UT-A1 and UT-A3 (3) and UT-B (1, 23) are important in maintaining the high inner medullary solute concentration required for the production of concentrated urine.
The largest renal UT-A isoform is UT-A1, consisting of 930 amino acids in the mouse (929 in the rat), while UT-A2 consists of the COOH-terminal 397 amino acids of UT-A1, and UT-A3 consists of the NH 2 -terminal 461 amino acids (460 in rat). UT-A1 and UT-A3 are located in the inner medullary collecting duct (IMCD), whereas UT-A2 has been localized to type 1 and type 3 thin descending limbs (2, 12, 21) . In terms of subcellular localization, UT-A1 has been located to the apical membrane of IMCD cells (9) , while UT-A2 is found on both apical and basolateral membranes of the thin descending limbs (2) . In contrast, UT-A3 has been localized to the basolateral membrane of IMCD cells in both the mouse (18) and rat (8, 13) , and also apically in the rat (20) .
UT-A1 and UT-A3 transporters localized in the IMCD regulate urea reabsorption into the interstitium, under the control of arginine vasopressin (AVP) (3) . In rat perfused, isolated IMCD, AVP has been shown to increase intracellular levels of cAMP and calcium, as well as stimulating trans-epithelial phloretin-sensitive urea transport (17, 22) . Recent studies of rat UT-A1 (4) and mouse UT-A2 (10) expressed in Madin-Darby canine kidney (MDCK) type I cell lines showed that both isoforms can be acutely regulated by AVP, probably via a cAMP-dependent pathway. Interestingly, while the cAMP stimulation of UT-A1 is known to be sensitive to a PKA inhibitor, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide.2HCl (H89) (24) , our recent study suggests that cAMP activation of mUT-A2 is in fact PKA independent (10) .
When expressed in HEK-293 cells or Xenopus laevis oocytes, UT-A3 is activated by cAMP (2, 7), although nothing is yet known about the mechanism of this activation. In this study, we have engineered an MDCK type I cell line that stably expresses mouse UT-A3 protein (i.e., MDCK-mUT-A3) and used this to show that mUT-A3 is sensitive to AVP. Furthermore, we have shown that mUT-A3 is also sensitive to increases in cAMP or calcium and that H89 blocks the AVP response but not the calcium response.
METHODS

Establishment of MDCK-mUT-A3 cells.
MDCK cells stably transfected with pFRT/lacZeo (Invitrogen; termed "MDCK-FLZ" cells) and MDCK-FLZ cells stably expressing rat UT-A1 (termed MDCKrUT-A1) were the kind gift of the late Dr. Robert Gunn (Emory University, Atlanta, GA). Cells were cultured as previously described (4) . MDCK-FLZ cells stably expressing mouse mUT-A3 (termed MDCK-mUT-A3) were derived using the Flp-In system (Invitrogen) as follows. Sequence encoding a c-myc tag was incorporated into the open reading frame of mUT-A3 cDNA immediately 5Ј to the stop codon by PCR/plasmid subcloning. This incorporated sequence encoded for 10 amino acids (EQKLISEEDL), a stop codon, and a Spe1 restriction site. To verify correct incorporation, restriction digests and nucleotide sequencing were performed.
The UT-A3 c-myc construct was subcloned into pcDNA5/FRT (Invitrogen) and cotransfected with pOG44 into the MDCK-FLZ cells using an Amaxa nucleofector (Amaxa, Cologne, Germany) according to the manufacturer's instructions. Cells were selected with 300 g/ml hygromycin after 24 h, and individual clones were isolated after 2 wk. Three clonal cell lines were isolated (termed EP15, EP16, and EP17), and protein expression was assessed using semiquantitative immunoblotting (see below for details).
Epithelial monolayers were cultured on semipermeable polyester supports (0.4-m pore, Transwell, Corning) as described elsewhere (4) . Monolayers were fed on day 2 following seeding, then daily until use. The resistance of each monolayer was measured using an EVOM resistance meter (World Precision Instruments). After confluence, membranes developed a transmembrane resistance Ͼ1.0 k⍀. Only membranes that showed sequential increases in transmembrane resistance to Ն1.0 k⍀ were used for flux experiments.
Immunoblotting. Cells from various MDCK cell lines (MDCK-FLZ, MDCK-rUT-A1, MDCK-mUT-A2, MDCK-mUT-A3) were harvested separately using 0.05% trypsin-EDTA (GIBCO) and washed twice with PBS. Cell protein was homogenized with a handheld dounce homogenizer, using a standard homogenization buffer (pH 7.6) containing 12 mM HEPES, 300 mM mannitol, and peptidase inhibitors added immediately before use (1 g/ml pepstatin, 2 l/ml leupeptin, and 1 g/ml phenylmethylsulfonyl fluoride, Sigma). Homogenates were initially centrifuged at 2,500 g for 15 min at 4°C, and then the resulting supernatant was centrifuged at 200,000 g for another 30 min at 4°C. These plasma membrane-enriched pellets were retained and resuspended in homogenization buffer. Immunoblotting experiments were then performed using the protocol previously described (18) . Briefly, SDS-PAGE was performed on minigels of 10% polyacrylamide by loading 20 g protein/lane. After transfer to nitrocellulose membranes, immunoblots were probed for 16 h at 4°C with an affinity-purified antiserum, ML446, previously shown to detect UT-A1 and UT-A3 (18) . Immunoblots were then washed and probed with 1:5,000 dilution of goat anti-rabbit horseradish peroxidase (HRP)-linked secondary antiserum (Dako) for 1 h at room temperature. After further washing, detection of protein was performed using ECL Western Blotting Detection Reagents and ECL film (Amersham Pharmacia).
Flux measurements. Trans-epithelial urea flux experiments were performed as previously described (10) at 37 Ϯ 0.2°C, in an apical-tobasolateral direction, using [ 14 C]urea (0.8 Ci/apical well) as the radiolabeled tracer. The basolateral solution was collected at 3-min intervals.
"Unidirectional basolateral uptake" urea flux experiments were performed at 37 Ϯ 0.2°C, using [ 14 C]urea (1.0 Ci/basolateral well)
as the radiolabeled tracer. Transwells were initially incubated in HBSS media (GIBCO) containing 5 mM urea, 12 mM HEPES, and the specific test compounds. After the relevant incubation time period, they were then placed in HBSS basolateral solution containing [ 14 C]urea for between 0.5 and 5 min, with or without test compounds present. This was followed by 10 s in a basolateral solution consisting of standard 1ϫ PBS containing 10 mM cold urea. Transwells were then removed from the basolateral solution completely, and the apical HBSS solution was replaced with 500 l 5% SDS solution (see Fig. 3 ). Cells were allowed to dissolve for 45 min on a horizontal shaker. SDS-cell suspensions were then transferred into scintillation vials, 3 ml of Ecoscint A (National Diagnostics) scintillation fluid were added to each vial, and the radioactivity was counted using a 1900 TR liquid scintillation analyzer (Packard, Canberra, Australia).
All test compounds were of certified grade and were made up either in sterile dH 2O or anhydrous DMSO. Stocks solutions were 100 M AVP in dH2O; 50 M forskolin in DMSO; 50 mM 8-bromo-cAMP in dH2O; 1 mM ATP in dH2O; 10 mM H89 in DMSO; 500 mM 1,3 dimethyl urea (DMU) in dH2O; and 100 mM phloretin in DMSO. Stocks were then diluted in Hank's balanced salt solution (GIBCO) containing 5 mM urea and 12 mM HEPES before use. Control solutions were prepared by adding the corresponding solvent minus the test compound.
X. laevis oocyte expression experiments. These were performed as previously described (15) . Briefly, a plasmid containing mUT-A3 was linearized, and cRNA was prepared using the T7 mMessage mMachine (Ambion). Defolliculated oocytes were injected with either 0.6 ng mUT-A3 cRNA or deionized water and incubated for 3 days at 18°C. To investigate the effect of vasopressin, 
RESULTS
Semiquantitative immunoblotting of MDCK-mUT-A3 cell lines.
Following transfection of MDCK-FLZ cells with the pcDNA5/FRT/mUT-A3 construct, a hygromycin-resistant clone, termed EP16, was selected and expanded. Using the previously characterized UT-A1/UT-A3-selective antiserum ML446 (18) , immunoblotting analysis of the EP16 mUT-A3 cell line, a MDCK-rUT-A1 cell line (4), a MDCK-mUT-A2 cell line (10) , and a MDCK-FLZ control cell line was performed. A signal of ϳ85 kDa was detected in the MDCK-rUT-A1 cell line, corresponding to unglycosylated rUT-A1, while no signals were detected for the MDCK-FLZ or MDCK-mUT-A2 cell lines (see Fig. 1A ). In contrast, a doublet signal centered at ϳ40 kDa was detected for MDCK-mUT-A3, similar to that previously reported for unglycosylated mUT-A3 protein (18) . Immunoblotting of EP16 and two other UT-A3 cell lines (EP15 and EP17) confirmed the presence of a ϳ40-kDa signal in all MDCK-mUT-A3 cell lines and showed that EP16 displayed the highest level of protein expression (see Fig. 1B ). The EP16 cell line was subsequently utilized for all MDCK-mUT-A3 urea flux experiments.
X. laevis oocyte expression experiments. To test the hypothesis that mUT-A3 function could be regulated by vasopressin, preliminary tests were performed in X. laevis oocytes. Under control conditions, oocytes injected with 0.6 ng of mUT-A3 cRNA displayed a twofold increase in urea uptake compared with water-injected controls (27 Ϯ 3 pmol ⅐ oocyte Ϫ1 ⅐ 90 s
Ϫ1
, n ϭ 7, cf. 13 Ϯ 3 pmol ⅐ oocyte Ϫ1 ⅐ 90 s Ϫ1 , n ϭ 8, P Ͻ 0.05, ANOVA). Importantly, 1-h preincubation with 10 Ϫ6 M AVP significantly stimulated uptake in mUT-A3-injected oocytes (41 Ϯ 3 pmol⅐oocyte Ϫ1 ⅐90 s Ϫ1 , n ϭ 6, P Ͻ 0.05, ANOVA) but had no effect on water-injected controls [18 Ϯ 3 pmol⅐oocyte Ϫ1 ⅐90 s Ϫ1 , n ϭ 7, not significant (NS), ANOVA] (see Fig. 2 ). These results showed that wild-type mUT-A3 is sensitive to AVP.
Functional analysis of MDCK-mUT-A3 monolayers: transepithelial flux.
Trans-epithelial urea flux rates were measured for confluent monolayers of different MDCK cell lines grown separately on Transwell membranes, as previously described by Potter et al. (10) . Control MDCK-FLZ monolayers had a trans-epithelial urea flux of 0.4 Ϯ 0.1 nmol⅐min Ϫ1 ⅐cm Ϫ2 (n ϭ 4). MDCK-mUT-A2 monolayers had a significantly higher urea flux rate of 3.2 Ϯ 0.2 nmol⅐min Ϫ1 ⅐cm Ϫ2 (n ϭ 4, P Ͻ 0.001, ANOVA). MDCK-mUT-A3 monolayers in comparison had a trans-epithelial urea flux of 0.5 Ϯ 0.1 nmol⅐min Ϫ1 ⅐cm
Ϫ2
(n ϭ 4, NS, ANOVA) that was not different from that observed for control MDCK-FLZ cells (see Fig. 3A ). The addition of 10 Ϫ6 M AVP had no effect on trans-epithelial urea flux in MDCK-mUT-A3 monolayers (n ϭ 3, NS, ANOVA) (see Fig.  3B ), even though this had previously been shown to increase trans-epithelial flux in MDCK-mUT-A2 cells within 5 min (10). Exposure to 250 M 8-bromo-cAMP was also found to have no effect on MDCK-mUT-A3 trans-epithelial urea transport (n ϭ 3, NS, ANOVA, data not shown).
Functional analysis of MDCK-mUT-A3 monolayers: basolateral flux. The lack of AVP-stimulated trans-epithelial urea transport in MDCK-mUT-A3 monolayers suggested that functional mUT-A3 transporters were not present on both apical and basolateral membranes. Since mUT-A3 has previously been shown to localize to the basolateral membrane (18) , specific unidirectional urea flux rates across the basolateral membrane were measured for the different MDCK cell lines (see Fig. 4 ). The time course of 14 C-labeled urea basolateral uptake into MDCK-mUT-A3 monolayers was calculated by measuring the cellular urea content after uptake periods of between 0.5 and 5 min (see Fig. 5A ). These data illustrated that the uptake of urea was reasonably linear within the first minute and had not reached a maximum; hence simpler basolateral uptake experiments could be performed using a 1-min uptake period. Under basal conditions, basolateral urea flux in MDCK-mUT-A3 cells (2.0 Ϯ 0.2 nmol⅐min Ϫ1 ⅐cm Ϫ2 , n ϭ 16) was not significantly different to that measured in MDCK-FLZ monolayers (1.7 Ϯ 0.2 nmol⅐min Ϫ1 ⅐cm Ϫ2 , n ϭ 16, NS, ANOVA) (see Fig. 5B ), in contrast to that observed in MDCKmUT-A2 cells (2.5 Ϯ 0.1 nmol⅐min Ϫ1 ⅐cm Ϫ2 , n ϭ 20, P Ͻ 0.05, ANOVA). These results again indicated that mUT-A3 was not functional in MDCK-mUT-A3 cells under basal conditions. M AVP has no effect on trans-epithelial urea flux in MDCK-mUT-A3 monolayers. ***P Ͻ 0.001 vs. control MDCK-FLZ data.
The effect of AVP on basolateral urea uptake was then investigated. Pretreatment of MDCK-mUT-A3 monolayers to 10 Ϫ8 M AVP for 1 h significantly increased basolateral urea uptake (n ϭ 4, P Ͻ 0.05, ANOVA) (see Fig. 5C ) compared with control data, suggesting AVP activates basolateral UT-A3 urea transport. Interestingly, AVP caused an increase in both the initial influx rate within the first minute and the final total cellular urea content after 5 min, suggesting that the maximum cellular urea content had increased. Next, the effect of different durations of exposure to a high concentration of AVP (10 Ϫ6 M) was investigated in various MDCK cell lines, using only 1-min uptake periods. Importantly, preincubation of MDCK-FLZ cells in 10 Ϫ6 M AVP had no effect on the basolateral urea flux after either 10 or 60 min (n ϭ 4, NS, ANOVA) (see Fig. 5D ). Although the increase in MDCK-mUT-A2 basolateral urea flux caused by 10 Ϫ6 M AVP was not significant (n ϭ 4, NS, ANOVA), the resulting flux after 60-min exposure was significantly greater than that observed in MDCK-FLZ cells (P Ͻ 0.05, ANOVA) (see Fig. 5D ). In contrast, acute exposure to AVP significantly increased the urea uptake of basolateral membranes in MDCK-mUT-A3 cells within 5 min (n ϭ 4, P Ͻ 0.05, ANOVA), with an initial peak stimulation of urea transport occurring after 10 min of AVP exposure, followed by a further increase after 60 min (n ϭ 4, P Ͻ 0.01, ANOVA) (see Fig. 5D ). Importantly, the AVP stimulation of MDCKmUT-A3 urea transport was not confined to high doses. Indeed, a significant increase was observed after 10-and 60-min exposures to doses as low as 10 Ϫ12 M AVP (n ϭ 4, P Ͻ 0.05, ANOVA), although these stimulatory effects were not as great as those observed with 10 Ϫ10 or 10 Ϫ6 M AVP (see Fig. 6 ). To confirm that the AVP-stimulated increase in urea transport was indeed due to regulation of mUT-A3, the effects of known inhibitors of facilitative urea transporters were investigated. Addition of DMU had no effect on basal urea transport in MDCK-mUT-A3 cells (n ϭ 4, NS, ANOVA). However, the increased urea transport induced by 10-min exposure to AVP was completely inhibited in the presence of 50 mM DMU (n ϭ 4, P Ͻ 0.05, ANOVA) (see Fig. 7 ). Phloretin (500 M) also significantly inhibited the urea transport stimulated by 60-min exposure to AVP (n ϭ 4, P Ͻ 0.05, ANOVA), despite having no effect in basal conditions (n ϭ 4, NS, ANOVA) (see Fig. 8 ).
It is known that exposure of the IMCD to AVP can lead to increases in intracellular levels of both cAMP and calcium, e.g., in rat isolated, perfused IMCD (17) . The effects of increasing either intracellular cAMP or calcium on MDCKmUT-A3 urea transport were therefore investigated. The application of 30 M forskolin was used to increase intracellular cAMP and resulted in a significant increase in urea transport after 10 min (n ϭ 4, P Ͻ 0.01, ANOVA) (see Fig. 9A ), as did the addition of 250 M 8-bromo-cAMP (n ϭ 4, P Ͻ 0.05, ANOVA, data not shown). Raising intracellular levels of 14 C]urea and test compounds for between 0.5 and 5 min. B: Transwell membrane was then washed in basolateral solution of 1ϫ PBS plus 10 mM cold urea for 10 s. C: after basolateral and apical solutions were removed, the apical chamber was filled with 500 l 5% SDS solution and placed on platform shaker for 45 min. The level of radioactive [ 14 C]urea in each cell suspension was then counted using a scintillation counter. Ϫ8 M AVP data. *P Ͻ 0.05, **P Ͻ 0.01 between control and AVP data. D: effect of up to 60-min preincubation with 10 Ϫ6 M AVP on basolateral urea uptake in MDCK cell line monolayers (all n ϭ 4), using 1-min uptake periods. AVP significantly stimulated urea flux in MDCK-mUT-A3 monolayers within 5 min, with a further increase after 60 min, but had no effect on control MDCK-FLZ monolayers and only a small effect on MDCK-mUT-A2 monolayers. *P Ͻ 0.05, **P Ͻ 0.01 vs. 0-min AVP exposure data.
calcium by the addition of 1 mM ATP also significantly increased urea transport within 10 min (n ϭ 4, P Ͻ 0.05, ANOVA) (see Fig. 9B ).
Since PKA has previously been indicated to play a role in vasopressin regulation of rat UT-A1 (24), the effect of a specific PKA inhibitor, H89, was investigated. Interestingly, 1-h preincubation with 10 M H89 completely prevented the increase in urea transport observed with 10-min exposure to AVP (n ϭ 4, P Ͻ 0.05, ANOVA) (see Fig. 10A ). In comparison, H89 had no effect on the ATP stimulation of urea transport in MDCK-mUT-A3 cells (see Fig. 10B ), suggesting PKA does not mediate the calcium-activated stimulation of the mUT-A3 transporter. Overall, these results strongly suggest a role for PKA in the AVP stimulation of DMU-sensitive mUT-A3 transporters when they are expressed in MDCK cells.
DISCUSSION
The regulation of renal UT-A urea transporters by the central antidiuretic hormone vasopressin is vital to the urinary concentrating mechanism and hence overall water balance. There are three major renal UT-A isoforms involved in this process: UT-A1, UT-A2, and UT-A3. Previous studies utilizing MDCK cells stably expressing rUT-A1 (4) and mUT-A2 (10) have shown both of these isoforms are acutely regulated by AVP. In the present study, we have engineered an MDCK type I cell line that expresses mUT-A3 and investigated its functional properties, including acute AVP regulation.
Immunoblotting of clonally selected mUT-A3-transfected MDCK cells confirmed that all three of the cell lines (EP15-17) expressed significant amounts of mUT-A3 protein. The 40-kDa signal detected by the ML446 antibody in MDCK-mUT-A3 cells corresponds to the size of unglycosylated mUT-A3 previously reported in mouse IMCD tissue, where a 45-to 65-kDa mUT-A3 signal was deglycosylated to 40 kDa (18) . Since EP16 expressed the highest level of mUT-A3 protein, this cell line was utilized for all further experiments. Importantly, these data indicated that we successfully engineered the first renal epithelial cell line to stably, heterologously express mUT-A3.
MDCK-mUT-A3 cells formed high-resistance (Ͼ1.0 k⍀/ cm 2 ) tight epithelial monolayers that under basal nonstimulated conditions had the same trans-epithelial urea flux as untransfected MDCK-FLZ control monolayers. Preliminary data had shown that wild-type mUT-A3 expressed in X. laevis oocytes was significantly stimulated by acute exposure to AVP, but exposure to AVP had no effect on the MDCK-mUT-A3 transepithelial urea flux. This suggests that functional mUT-A3 transporters were not present on both apical and basolateral membranes. Since we have previously reported that mUT-A3 transiently expressed in MDCK type II cells is localized to the basolateral membrane (18), we investigated the unidirectional basolateral membrane urea permeability in MDCK-mUT-A3 monolayers, but this was again no different from control levels. This suggests that mUT-A3 protein exhibits a lack of activity under basal conditions when expressed in MDCK cells. In contrast, high basal urea transporter activity has previously been observed in MDCK-mUT-A2 cells (10). Ϫ12 , 10 Ϫ10 , or 10 Ϫ6 M AVP. Urea fluxes are shown for both 10-and 60-min exposures for each AVP concentration, and all concentrations produced a significant increase in urea flux. *P Ͻ 0.05, **P Ͻ 0.01 vs. control data. Fig. 7 . Effect of the urea analog DMU on basolateral urea flux in MDCKmUT-A3 monolayers. 1,3 Dimethyl urea (DMU; 50 mM) had no effect on basolateral urea flux under basal conditions, but completely inhibited the significant increase observed with 10-min exposure to 10 Ϫ6 M AVP. *P Ͻ 0.05 vs. control data. Fig. 8 . Effect of phloretin, an inhibitor of facilitative urea transporters, on basolateral urea flux in MDCK-mUT-A3 monolayers. Phloretin (500 M) had no effect on basolateral urea flux under basal conditions but significantly inhibited the substantial increase observed with 60-min exposure to 10 Ϫ6 M AVP. *P Ͻ 0.05 vs. AVP alone data.
We next investigated the effects of AVP on unidirectional basolateral urea uptake. The addition of AVP had no effect on MDCK-FLZ basolateral urea uptake whatsoever, and only a small stimulatory effect on MDCK-mUT-A2 cells. In contrast, AVP significantly increased the urea transport in MDCKmUT-A3 cells, indicating stimulated urea transport via basolateral mUT-A3 transporters. The possibility that AVP stimulation was due to the c-myc tag present in the mUT-A3 protein can be ruled out since wild-type UT-A3 expressed in X. laevis oocytes also responded to AVP. The AVP regulation of urea transport observed in MDCK-mUT-A3 cells occurred within 5 min, initially peaked at 10 min, and was maintained for at least 60 min (see Fig. 5D ). Importantly, similar increases were observed with both high (10 Ϫ6 M) and low (10 Ϫ12 M) doses of AVP. Since circulating concentrations of AVP in vivo are 10 Ϫ11 to 10 Ϫ12 M, this finding strongly suggests the response is physiologically relevant. It is important to note that the precise nature of AVP's action on UT-A3 urea transport remains unclear. While AVP does significantly increase initial basolateral urea flux in MDCK-mUT-A3 cells, the fact that it also increases final cellular urea content after 5 min (see Fig.  5C ) suggests an additional effect is also occurring. There are two distinct explanations for the increase in cellular urea content: First, AVP may stimulate active urea transport in MDCK cells. However, whether MDCK cells endogenously express active urea transporters has not been determined. Second, AVP treatment may cause an increase in cell volume either by its effect on urea transporter proteins or independently of this action. Clearly, these observations provide fuel for future experiments.
The AVP-stimulated increase in urea transport was confirmed to be mUT-A3 mediated by the fact that it was significantly inhibited by DMU and phloretin, both known inhibitors of facilitative urea transporters. These results strongly suggest that mUT-A3 localizes to the basolateral membrane in MDCK type I cells, in agreement with previous localization in MDCK type II cells, mouse IMCD (18) , and rat IMCD (8) . The lack of effect of both phloretin and DMU under basal conditions also confirmed that UT-A3 remained completely inactive in the absence of AVP.
Similar to the results observed for mUT-A2 (10), increases in intracellular levels of either cAMP or calcium were able to stimulate UT-A3 urea transport. Although further investigations are required to elucidate the exact mechanism of AVP stimulation of UT-A3, it is highly likely that the response involves increases in intracellular cAMP, after the activation of basolateral V2 vasopressin receptors and involving the actions of calmodulin (6) . Although increases in intracellular calcium activate mUT-A3, as was also observed with rUT-A1 and mUT-A2 (10), it has previously been shown in the rat terminal IMCD that the AVP-elicited calcium transient is not involved in the stimulation of urea transport (5) . In addition, a very large dose of ATP (1 mM) is required to elicit a significant response, both for UT-A3 in the present study and previously for UT-A2 (10), where 10 M ATP had no effect (Stewart GS and Smith CP, unpublished observations). This finding suggests that while urea transporters can be stimulated by large increases in calcium, their acute regulation does not primarily involve whole-scale changes in intracellular calcium levels. However, it must also be considered that calmodulin, a calcium binding protein, is required for vasopressin stimulation of adenylate cyclase-dependent cAMP production in the IMCD (6) .
Importantly, acute AVP stimulation of mUT-A3 urea transport was shown to be PKA dependent, since it was inhibited by H89, a PKA inhibitor. In this manner, AVP regulation of mUT-A3 appears similar to that of rUT-A1 (24), rather than 10 . A: effect of H89, an inhibitor of PKA, on AVP-stimulated basolateral urea flux in MDCKmUT-A3 monolayers. Although preincubation for 1 h with 10 M H89 had no effect on basolateral urea flux under basal conditions, it completely inhibited the significant increase observed with 10-min exposure to 10 Ϫ6 M AVP. B: in contrast, H89 had no effect on the stimulation of urea transport observed with 10-min exposure to 1 mM ATP, after it again had no effect under basal conditions. *P Ͻ 0.05 vs. control data.
that of mUT-A2 (10) . This also suggests that the PKA-responsive element in UT-A1 regulated by AVP lies within the 461 NH 2 -terminal amino acids. The fact that ATP-induced activation of mUT-A3 was not dependent on PKA is further evidence that AVP is primarily stimulating urea transport through a cAMP-dependent pathway, rather than a calcium-dependent pathway. It is therefore also likely that AVP facilitates the phosphorylation of mUT-A3 in a manner similar to that observed for UT-A1, where AVP has been shown to phosphorylate both UT-A1 in rat IMCD, via a PKA-dependent pathway (24) , and UT-A1 expressed in MDCK cells (4) .
At present, it remains unclear whether AVP activates mUT-A3 transporters already present in the basolateral membrane, whether it facilitates acute trafficking of mUT-A3 to the membrane, or a combination of both. The AVP stimulation of urea transport in MDCK-mUT-A3 cells appears similar to the response previously observed for AVP stimulation of urea transport in rat IMCD, where an initial rapid increase occurred within 10 min, followed by a slower increase over the next 30 min (17, 22) . However, due to the possible limitations of basolateral uptake measurements, caution must be taken not to draw definitive conclusions concerning the nature of AVP activation of UT-A3 at this stage. Interestingly, however, while the rat IMCD responses were observed with 10 Ϫ11 M AVP, maximal stimulation only occurred with 10 Ϫ8 M AVP (17), again similar to the dose response for mUT-A3 stimulation observed in this report. Our data concerning acute regulation of mUT-A3 urea transport are therefore consistent with results observed for urea transport in the IMCD, the tissue that expresses UT-A3 transporters. It is interesting to consider that AVP could be increasing IMCD urea permeability by activating urea transporters on both membranes, namely, UT-A1 on the apical membrane and UT-A3 on the basolateral membrane. The overall effect would therefore be a composite of both UT-A1 and UT-A3 activation and future study of individual UT-A isoforms, expressed in MDCK cells, may lead to understanding the exact components of vasopressin-regulated IMCD urea permeability.
In conclusion, we have engineered the first renal cell line that heterologously expresses mUT-A3. When expressed in MDCK type I cells, mUT-A3 localizes to the basolateral membrane and is responsible for a urea flux that can be acutely activated by AVP. This AVP-stimulated urea transport is sensitive to DMU and phloretin, and is also PKA dependent. Regulation of mUT-A3 also occurs with increases in intracellular levels of either cAMP or calcium. These findings have important implications for the regulation of urea transport in the renal IMCD and the urinary concentrating mechanism.
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